Sacituzumab govitecan response in extensive leptomeningeal carcinomatosis from triple-negative breast cancer: a case report

• DOI: 10.3389/fonc.2024.1378248
• Publication Date: 2024-08-12T04:29:59Z
• Authors: Jesús Yaringaño; María Roca-Herrera; Simeón Eremiev; Pau Mascaró-Baselga; Pau Benito; Fidel Núñez; Sergi Benavente; Isabel Pimentel
• Keywords: Triple-negative breast cancer; Antibody-drug conjugate

Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate (ADC), was the first ADC approved for patients with metastatic triple-negative breast cancer (mTNBC) who had received at least two prior lines of therapy advanced disease. Although SG has shown promising clinical activity in treating brain metastases both ASCENT randomized trials and real-world analysis, its utility leptomeningeal carcinomatosis (LC) remains underexplored. We report diagnostic therapeutic process patient develops extensive LC from TNBC treated SG. She presented response after cycle PFS 6 months. This case highlights need further inquiry into use LC.